Cysteinyl leukotrienes in asthma: old mediators up to new tricks

The cysteinyl leukotrienes have long been suspected to play a role in the pathogenesis of asthma. This speculation was based largely on their release in human lung following antigen challenge as well as their potent bronchoconstrictor activity. However, there is increasing evidence that the cysteiny...

Full description

Saved in:
Bibliographic Details
Published in:Trends in Pharmacological Sciences 1995-09, Vol.16 (9), p.304-309
Main Authors: Hay, Douglas W.P., Torphy, Theodore J., Undem, Bradley J.
Format: Article
Language:English
Subjects:
Animals
Anti-Asthmatic Agents - pharmacology
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy
Asthma - physiopathology
Humans
Inflammation Mediators - antagonists & inhibitors
Inflammation Mediators - physiology
Leukotriene Antagonists
Leukotrienes - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cysteinyl leukotrienes have long been suspected to play a role in the pathogenesis of asthma. This speculation was based largely on their release in human lung following antigen challenge as well as their potent bronchoconstrictor activity. However, there is increasing evidence that the cysteinyl leukotrienes also produce several pro-inflammatory effects and alter the activity of neuronal pathways in the airways. Douglas Hay, Theodore Torphy and Bradley Undem review these recent data and discuss the therapeutic possibilities of cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
ISSN:0165-6147
1873-3735
DOI:10.1016/S0165-6147(00)89059-8